Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
Essen Biotech
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eli Lilly and Company
Var2 Pharmaceuticals
University Health Network, Toronto
British Columbia Cancer Agency
Guangzhou FineImmune Biotechnology Co., LTD.
Washington University School of Medicine
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
Turning Point Therapeutics, Inc.
University of California, Irvine
Cancer Research UK
Elevation Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Rutgers, The State University of New Jersey
Actuate Therapeutics Inc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
National Cancer Institute (NCI)
Zhejiang Provincial People's Hospital
Washington University School of Medicine
Second Affiliated Hospital of Guangzhou Medical University
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
RefleXion Medical
pharmaand GmbH
M.D. Anderson Cancer Center
Kineta Inc.
Shanghai Yunying Medical Technology
Shanghai Yunying Medical Technology
Prelude Therapeutics
Quadriga Biosciences, Inc.
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Celgene
InSightec
National Institutes of Health Clinical Center (CC)